Researcher.Life Logo

Annals of the Rheumatic Diseases : Impact Factor & More

eISSN: 1468-2060pISSN: 0003-4967

Aims and Scope of Annals of the Rheumatic Diseases

The Annals of the Rheumatic Diseases is a peer-reviewed medical journal. It is co-owned by the BMJ Group and the European League Against Rheumatism and covers all aspects of rheumatology, including musculoskeletal conditions, arthritis, and connective tissue diseases. The journal publishes basic, clinical, and translational research and abstracts from conferences. The journal was established in 1939. It is available online by subscription and archived editions of the journal (older than one year) are available free of charge. Each issue, the editor-in-chief selects a paper to be published open access as an "Editors Choice". The editor-in-chief is Josef Smolen. Less

Key Metrics

CiteScore
28.5
Eigenfactor
0.05 - 0.1
H-Index
272
Impact Factor
>= 25
Scite Index
0.88 5-Year SI
SJR
Q1Immunology
SNIP
5.22
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Annals of the Rheumatic Diseases

Annals of the Rheumatic Diseases Journal Specifications

Overview
Publisher BMJ PUBLISHING GROUP
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1935
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Annals of the Rheumatic Diseases ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Annals of the Rheumatic Diseases

Correspondence on 'Deconstruction of tophi and synovium defines SPP1+ macrophages involved in extracellular matrix remodelling in gout' by Xu et al.
  • 22 Nov 2025
  • Annals of the rheumatic diseases
Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study.
  • 20 Nov 2025
  • Annals of the rheumatic diseases
Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis.
  • 20 Nov 2025
  • Annals of the rheumatic diseases
Clinical and biologic predictors of thrombosis in persistently antiphospholipid antibody-positive patients: Prospective analysis of the International APS ACTION Clinical Database and Repository ('Registry').
  • 19 Nov 2025
  • Annals of the rheumatic diseases
Development and validation of a EULAR disease activity score in antiphospholipid syndrome.
  • 19 Nov 2025
  • Annals of the rheumatic diseases
A de novo dominant-negative PSMB8 mutation causes severe CANDLE/PRAAS due to arrested proteasome biogenesis.
  • 17 Nov 2025
  • Annals of the rheumatic diseases
Correspondence on 'Deconstruction of tophi and synovium defines SPP1+ macrophages involved in extracellular matrix remodelling in gout' by Xu et al.
  • 22 Nov 2025
  • Annals of the rheumatic diseases
Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study.
  • 20 Nov 2025
  • Annals of the rheumatic diseases
Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis.
  • 20 Nov 2025
  • Annals of the rheumatic diseases
Clinical and biologic predictors of thrombosis in persistently antiphospholipid antibody-positive patients: Prospective analysis of the International APS ACTION Clinical Database and Repository ('Registry').
  • 19 Nov 2025
  • Annals of the rheumatic diseases
Development and validation of a EULAR disease activity score in antiphospholipid syndrome.
  • 19 Nov 2025
  • Annals of the rheumatic diseases
A de novo dominant-negative PSMB8 mutation causes severe CANDLE/PRAAS due to arrested proteasome biogenesis.
  • 17 Nov 2025
  • Annals of the rheumatic diseases

FAQs on Annals of the Rheumatic Diseases